NanoSpot™ is the first ELISA based in vitro multiplex allergy test allowing simultaneous measurement of total IgE (tIgE) and specific IgE (sIgE) against a plethora of allergen extracts and molecular allergens.
Based on our test panel composition of 295 allergen extracts and molecular allergens, a near complete picture of each patient’s sensitization status is obtained. This is achieved by utilizing our proprietary nano-bead technology. Every allergen extract can be individually optimized for production.
Each patient sample runs simultaneously in triplicate, with positive and negative controls, for unsurpassed precision and accuracy. The dramatic test redundancy of the microarray platform enables high senitivity and specifity values that are >96%.
The NanoSpot™ assay protocol integrates a powerful Cross-reactive Carbohydrate Determinants (CCD’s) inhibitor during serum incubation, which will clear up the specific IgE results. This reduces the interpretative burden for physicians of CCD positive patients and increases the specificity and accuracy of our test results.
Our easy to read patient report offers integrated result interpretation guidance for each positive allergen and can be easily generated in 24 different languages.
NanoSpot™ vs Skin Testing
Our Medical Experts
NIH Board Certified Allergist with over 20 years of experience
Board Certified in Internal Medicine she proudly serves our patients and staff
Pharm-D specializing in sterile compounding and custom immunotherapy treatments